If used clinically, this drug is the solution to the fatal shortcomings of current anaesthetic practices.
BDR Pharmaceuticals and Varenyam Healthcare have announced the launch of Sugammadex - an innovative, first of its kind drug in over 10 years with novel ?cyclodextrin neuromuscular block (NMB) reversal properties. Sugammadex is a pioneer in anaesthetic drugs, offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular block (NMB) and removes anaesthetic effects from the body. Reversal agents which are currently available in the market cannot reverse deep NMB, and thus lead to various postoperative respiratory complications. If used clinically, this drug is the solution to the fatal shortcomings of current anaesthetic practices. Sugammadex is available as 2ml & 5ml single-dose vials. Commenting on the launch, Raheel Shah, Director, Business Development, BDR Pharmaceuticals Int
